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Abstract
Background: Mycoplasma pneumoniae is thought to be a common cause of respiratory tract infections (RTIs) in children.
The diagnosis of M. pneumoniae RTIs currently relies on serological methods and/or the detection of bacterial DNA in the
upper respiratory tract (URT). It is conceivable, however, that these diagnostic methods also yield positive results if M.
pneumoniae is carried asymptomatically in the URT. Positive results from these tests may therefore not always be indicative
of a symptomatic infection. The existence of asymptomatic carriage of M. pneumoniae has not been established. We
hypothesized that asymptomatic carriage in children exists and investigated whether colonization and symptomatic
infection could be differentiated by current diagnostic methods.
Methods and Findings: This study was conducted at the Erasmus MC–Sophia Children’s Hospital and the after-hours
General Practitioners Cooperative in Rotterdam, The Netherlands. Asymptomatic children (n= 405) and children with RTI
symptoms (n= 321) aged 3 mo to 16 y were enrolled in a cross-sectional study from July 1, 2008, to November 30, 2011.
Clinical data, pharyngeal and nasopharyngeal specimens, and serum samples were collected. The primary objective was to
differentiate between colonization and symptomatic infection with M. pneumoniae by current diagnostic methods,
especially real-time PCR. M. pneumoniae DNA was detected in 21.2% (95% CI 17.2%–25.2%) of the asymptomatic children
and in 16.2% (95% CI 12.2%–20.2%) of the symptomatic children (p= 0.11). Neither serology nor quantitative PCR nor
culture differentiated asymptomatic carriage from infection. A total of 202 children were tested for the presence of other
bacterial and viral pathogens. Two or more pathogens were found in 56% (63/112) of the asymptomatic children and in
55.5% (50/90) of the symptomatic children. Finally, longitudinal sampling showed persistence of M. pneumoniae in the URT
for up to 4 mo. Fifteen of the 21 asymptomatic children with M. pneumoniae and 19 of the 22 symptomatic children with M.
pneumoniae in this longitudinal follow-up tested negative after 1 mo.
Conclusions: Although our study has limitations, such as a single study site and limited sample size, our data indicate that
the presence of M. pneumoniae in the URT is common in asymptomatic children. The current diagnostic tests for M.
pneumoniae are unable to differentiate between asymptomatic carriage and symptomatic infection.
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Introduction
Mycoplasma pneumoniae is considered a major cause of upper and
lower respiratory tract infections (RTIs) and respiratory tract
disease (RTD) in humans, and particularly in children. Over one-
third of the childhood cases of community-acquired pneumonia
that require hospitalization are thought to be caused by M.
pneumoniae [1,2]. The current diagnosis of M. pneumoniae infections
relies on the detection of either serum antibodies against M.
pneumoniae or bacterial DNA in samples of the upper respiratory
tract (URT), as recommended in the guidelines published by the
British Thoracic Society and the Infectious Diseases Society of
America [1,2].
PCR-based methods are increasingly used in daily clinical
practice, as well as in clinical studies, for the detection of M.
pneumoniae because they provide fast and sensitive results in the
acute phase of an infection [3–5]. However, RTD caused by other
common bacterial pathogens (such as Streptococcus pneumoniae)
cannot yet be diagnosed by PCR because these pathogens are
asymptomatically carried in the human population at high rates.
Likewise, if M. pneumoniae is commonly carried asymptomatically in
the URT of children, the detection of this bacterial species may
not indicate a symptomatic infection. This would have major
implications for the interpretation of the results of current
diagnostic methods for M. pneumoniae RTIs and their use in
clinical management. Clinical management of M. pneumoniae RTI
in children mainly consists of administration of macrolides,
because M. pneumoniae is not susceptible to penicillins. In an
increasing number of countries resistant strains of M. pneumoniae
are rapidly emerging, and these are associated with prolonged
disease. In Asia, up to 90% of M. pneumoniae derived from clinical
samples is currently macrolide-resistant [6]. The frequent use of
macrolides in children probably contributes significantly to the
selection of macrolide-resistant strains [7]. Decreasing the use of
macrolides by improving diagnostic methods, or their interpreta-
tion, might therefore help to prevent macrolide resistance.
In contrast to numerous published studies on carriage of S.
pneumoniae in children, studies that specifically address asymptom-
atic carriage of M. pneumoniae have hitherto not been performed.
To our knowledge, this is the first study in which the current state-
of-the-art diagnostic method for M. pneumoniae RTI, i.e., PCR, is
evaluated using a symptomatic and an asymptomatic group of
children during a 3-y period of sampling. To our knowledge, this is
also the first study to investigate the presence of M. pneumoniae in
both symptomatic and asymptomatic children in a longitudinal
fashion, including collecting data on the occurrence of symptom-
atic infection during carriage. Although previous studies have
reported the presence of M. pneumoniae in seemingly healthy
individuals, these studies all suffered from drawbacks related to the
study design (such as the lack of an appropriate control group
and/or the lack of a follow-up study) or to limitations of the
diagnostic assays that were employed [8–15]. As a consequence,
clear conclusions concerning the existence and dynamics of
carriage of M. pneumoniae could thus far not be drawn. We
hypothesized that asymptomatic carriage in children exists and
investigated whether colonization and symptomatic infection
could be differentiated by current diagnostic methods. Secondary
objectives of the present study were to assess the possible
association between acute symptomatic M. pneumoniae infection
and children’s age, and to determine the influence of M. pneumoniae
genotype as well as viral and bacterial co-infections on the severity
of M. pneumoniae RTIs.
Methods
Ethics Statement
This observational study was approved by the Medical Ethics
Review Board of the Erasmus MC (NL20418.078.08) and was
conducted at the Erasmus MC–Sophia Children’s Hospital and
the after-hours General Practitioners Cooperative in Rotterdam,
The Netherlands. Written informed consent was obtained from all
parents and from children above the age of 12 y.
Study Design and Population
Study participants, aged 3 mo to 16 y, were enrolled between
July 1, 2008, and November 30, 2011, in two groups. The first
group, which will be referred to as ‘‘the asymptomatic group,’’ was
enrolled during admission for a planned elective surgical
procedure, unrelated to RTD, at the short-stay department of
the hospital. Exclusion criteria were a current RTI (based on
questionnaires and physical examination by the attending
anesthesiologist), the use of antibiotics in the past 2 d (7 d for
azithromycin), and severe concomitant disease (e.g., chronic lung
disease, cardiovascular disease, neoplasia, liver disease, kidney
disease, metabolic disease, or psychomotor impairment). Baseline
characteristics (Table 1) and information about RTIs in the
previous 2 mo were recorded using a standardized questionnaire.
Two study-team members collected respiratory and blood samples
just prior to the start of the surgical procedure, while the child was
under general anesthesia. Three to four weeks later, a question-
naire was completed by phone on development of RTIs in the
weeks after enrollment.
In the second group, i.e., ‘‘the symptomatic group,’’ children
diagnosed with RTI were enrolled at either the emergency
department of the hospital or the after-hours General Practitioners
Cooperative. Exclusion criteria were the same as for the
asymptomatic group, except for having a current RTI. A
standardized questionnaire was used to record baseline charac-
teristics, clinical symptoms, and diagnosis at the discretion of the
attending physician. Respiratory specimens and a capillary blood
sample were collected. Three to four weeks later, a second
capillary blood sample was collected and information was
recorded about the duration of the RTI, treatment, and
hospitalization.
Children who tested positive for M. pneumoniae by PCR were
invited to participate in a longitudinal follow-up study, from
August 1, 2010, to November 30, 2011. After informed consent
was obtained, each child was tested monthly for the presence of M.
pneumoniae in the URT until the test was negative on two
consecutive occasions.
Study Procedures
From each child, a pharyngeal swab (BBL CultureSwab EZ,
BD) was taken by gently stroking between the palatine arches
superior to the tonsils. The swab was stored in phosphate-buffered
saline. Subsequently, two nasopharyngeal specimens were taken.
First, a flexible swab (Copan) was inserted into one nostril, guided
to the posterior nasopharyngeal wall, removed, and stored in
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Amies transport medium. Second, 1 ml of normal saline was
instilled into each nostril and then suctioned by a flexible catheter
applied to a container. The catheter was rinsed with 2 ml of
normal saline. Specimens were kept at 4uC until further
preparation within hours of collection.
To prevent contamination of samples, we took the following
precautions. First, the two members of the study team who
performed all procedures tested M. pneumoniae PCR-negative
throughout the study period. Second, samples were prepared
and tested in different subunits of the laboratory. In a ‘‘nucleic
acid–free’’ laboratory, the samples were divided in aliquots used
for culture, nucleic acid isolation, and storage. In other laboratory
subunits, samples were either cultured or used for nucleic acid
isolation. Each step in the PCR procedure, i.e., the preparation of
real-time PCR premixes, the addition of purified nucleic acids to
these premixes, and the actual PCR reactions, were carried out in
different laboratories. Finally, each PCR run contained positive
and negative controls.
Detection of M. pneumoniae in the URT was performed by real-
time PCR and culture on both the pharyngeal swabs and the
nasopharyngeal washings. DNA isolation was performed on
200 ml of the original samples using the QIAamp DNA Mini Kit
(Qiagen). A quantitative real-time (TaqMan) PCR assay was used
to detect and quantify M. pneumoniae genomic DNA, as previously
described [16]. Adequate negative control samples were included
in each PCR run. Culture was performed using 100 ml of the
original sample [17]. Molecular (sub)typing of M. pneumoniae was
performed on M. pneumoniae–positive samples, using a pyrose-
quencing-based assay [16]. Rest material was stored at 280uC
until further use.
Serum was stored at 280uC. Detection of anti–M. pneumoniae–
specific antibodies was performed using Serion ELISA classic M.
pneumoniae kits (Clindia Benelux).
The nasopharyngeal swabs were used for the detection of S.
pneumoniae, Staphylococcus aureus, Haemophilus influenzae, and
Moraxella catarrhalis, following standard microbiological proce-
dures [18].
The batch-wise detection of viral nucleic acids was performed
after the enrollment was closed. As all samples were stored at
280uC, selected samples were thawed. For the detection of viral
nucleic acids, 60 ml of the original sample from a pharyngeal swab
was diluted 10-fold with Dulbecco’s Modified Eagle Medium to a
total of 600 ml. Internally controlled nucleic acid extraction (input
volume 200 ml, output volume 100 ml), subsequent (multiplex)
real-time PCR, and its quality control were performed as
described before [19]. A cycle threshold below 40 was considered
a positive result. Viruses were determined in all M. pneumoniae
PCR-positive children and in M. pneumoniae PCR-negative children
matched with respect to month and year of sampling as well as
age. There was missing data for 30 M. pneumoniae–positive
participants, and these participants could therefore not be
included in this analysis.
Outcome Variables and Statistical Analyses
All data were analyzed using software package SPSS version
16.0.1. The protocol-defined objectives were as follows (Text S1):
(1) to determine the distribution of genomic copy loads in both the
asymptomatic group and the symptomatic group to differentiate
carriage from infection and (2) to assess the age distribution of the
presence of M. pneumoniae in both symptomatic children and
asymptomatic children, and to determine the influence of M.
pneumoniae genotype as well as viral and bacterial co-infections on
the severity of M. pneumoniae RTIs.
The prevalence of a positive test result for M. pneumoniae was
calculated in both groups and compared using the x2 test. Groups
were compared for the distribution of bacterial loads (genomic
copy number) using the Mann-Whitney U test. p-Values below
0.05 were considered significant. Within the symptomatic group, a
child was defined as having a M. pneumoniae infection when at least
one of the samples from the child was found to be M. pneumoniae–
positive by serology, culture, or PCR. Within the asymptomatic
group, M. pneumoniae carriage was defined by a M. pneumoniae–
positive result obtained by either culture or PCR.
The children in the symptomatic group with a M. pneumoniae
infection were divided into two groups carrying the two M.
pneumoniae subtypes (i.e., subtype 1 and subtype 2), and into two
groups according to the presence of co-infections. Diagnosis (upper
or lower RTI) and hospitalization were used as proxies for severity
of disease. Groups were compared for these variables using the x2
test.
Table 1. Baseline characteristics of the 726 study participants.
Characteristic Asymptomatic Group (n=405) Symptomatic Group
Total (n=321)
Emergency Department
(n=131)
General Practitioners
Cooperative (n=190)
Age 5.17 (4.76) 2.65 (3.48) 2.18 (3.38) 2.97 (3.50)
Female 137 (34.1) 155 (48.0) 58 (44.3) 95 (50.0)
Immunizations 383 (96.0) 307 (95.3) 124 (95.4) 183 (96.3)
Parental Smoking 145 (36.4) 132 (41.1) 42 (31.8) 90 (47.6)
Family size $5 163 (39.6) 74 (23.2) 33 (25.2) 41 (21.6)
Day-care attendance 121 (30.5) 160 (50.5) 75 (58.1) 86 (45.7)
Prior RTI 129 (31.5) NA NA NA
Lower RTI (including pneumonia) NA 64 (20.4) 38 (29.5) 26 (14.1)
Pneumonia NA 35 (10.9) 27 (20.6) 8 (4.2)
Hospitalization NA 41 (13.5) 32 (25.2) 9 (5.1)
Data are n (percent), except for age, which is given as mean (standard deviation). ‘‘Immunizations’’ refers to being immunized per the national immunization program in
The Netherlands.
NA, not applicable.
doi:10.1371/journal.pmed.1001444.t001
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To identify possible factors that could determine the presence of
M. pneumoniae, subgroup analyses were done for variables that
could reasonably have an effect on M. pneumoniae prevalence
including age, gender, season and year of enrollment, family size,
active or passive smoking, and day-care attendance. Additional
variables in the symptomatic group were diagnosis and hospital-
ization. Additional variables in the asymptomatic group were RTI
prior to enrollment and RTI just following enrollment. These
variables were entered in multiple logistic regression analysis
regardless of their bivariate association. Because these were all
exploratory analyses, we did not adjust for multiple comparisons
and p,0.05 was considered significant. To test for collinearity we
calculated condition indices for the multivariate analyses. We
found a condition index of 9.9 for the asymptomatic group and a
condition index of 12.1 for the symptomatic group. Because both
values are below the generally accepted warning signal of 15, and
there were no strong correlations between the covariates, we
believe that multicollinearity was not a major problem in this
study.
To allow the inclusion of a sufficiently high number of M.
pneumoniae–infected children below the age of 5 y, we used a
precalculated sample size of 400 children #5 y and 100 children
.5 y in the symptomatic group based on an estimated prevalence
of M. pneumoniae of 10%. In the asymptomatic group we took the
same number. After enrollment of a total of 412 children in the
asymptomatic group, it was apparent that the study question on
the existence of carriage could be addressed. This was due to a
higher prevalence of M. pneumoniae than anticipated in the
asymptomatic group and in the symptomatic group. Because
additional enrollments would not have a significant influence on
the outcomes of the study, it was deemed unethical to subject
additional children to the study, and enrollment was subsequently
discontinued.
Results
A total of 726 children, aged 3 mo to 16 y, were enrolled in this
study from July 1, 2008, until November 30, 2011 (Figures 1 and
2). In the asymptomatic group, 405 children were enrolled.
Enrollment for this group started in January 2009. In the
symptomatic group, 321 children were enrolled. With respect to
age, sex, and time of enrollment of study participants, there were
no differences between the group of children for whom consent
was given (enrolled in the study) and the group of children for
whom consent was not given (Table S1).
We found that the prevalence of M. pneumoniae by real-time PCR
did not differ significantly (p=0.11) between the asymptomatic
group (21.2%, 95% CI 17.2%–25.2%, n=85) and the symptom-
atic group (16.2%, 95% CI 12.2%–20.2%, n=51). A significant
difference between the groups was also not found by culture: four
(1.0%, 95% CI 0.03%–1.97%) of the asymptomatic children and
five (1.6%, 95% CI 0.23%–2.97%) of the symptomatic children
were M. pneumoniae–positive (p=0.52). In the symptomatic group,
the prevalence of M. pneumoniae by real-time PCR did not differ
significantly (p=0.85) between the children with a lower RTI
(15.6%, 95% CI 11.6%–19.6%, n=10) and the children with an
upper RTI (15.9%, 95% CI 11.9%–19.9%, n=41).
In the asymptomatic group, multiple logistic regression analysis
showed that season and year of enrollment were significantly
related to prevalence of M. pneumoniae (Tables 2 and S2). In the
symptomatic group, we found the presence of M. pneumoniae to be
positively associated with enrollment in 2010 and 2011 (Table S3).
As shown in Table 3, none of the variables were independently
related to the prevalence of M. pneumoniae. The presence of M.
pneumoniae was not significantly associated with age or asthma-like
symptoms (Tables 2 and 3). The two subtypes of M. pneumoniae
were equally distributed between the two groups (Table S4).
Figure 1. Enrollment flow diagram. ED, emergency department; GPC, General Practitioners Cooperative.
doi:10.1371/journal.pmed.1001444.g001
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Figure 2. Monthly enrollments during the course of the study. The enrollments for the symptomatic group are represented above by a red
dotted line. The enrollments for the asymptomatic group are represented below by a blue dotted line. The solid lines represent the absolute number
of M. pneumoniae–positive participants. Enrollment for the asymptomatic group started in January 2009.
doi:10.1371/journal.pmed.1001444.g002
Table 2. Results from the multiple logistic regression analysis
for a positive M. pneumoniae PCR result in the asymptomatic
group.
Variable
Odds Ratio
(95% CI) p-Value
Age ($5 y) 0.96 (0.47–1.96) 0.91
Gender (female) 1.44 (0.81–2.56) 0.22
Season ,0.001 (overall)
Spring versus winter 0.81 (0.33–1.97) 0.64
Summer versus winter 7.43 (3.09–17.85) ,0.001
Autumn versus winter 2.90 (1.26–6.70) 0.01
Year (2009 versus
2010 and 2011)
3.31 (1.75–6.27) ,0.001
Family size
($5 family members)
1.55 (0.77–3.13) 0.22
Smoking (active or passive) 0.70 (0.38–1.26) 0.23
Presence or history of wheezing 2.30 (0.69–7.61) 0.17
Day-care attendance 0.82 (0.38–1.77) 0.62
RTI prior to enrollment 0.95 (0.50–1.79) 0.86
RTI post-enrollment 0.59 (0.29–1.20) 0.15
The variable ‘‘immunizations’’ was not entered in the regression analysis
because the vast majority of the children were immunized (.95%).
doi:10.1371/journal.pmed.1001444.t002
Table 3. Results from the multiple logistic regression analysis
for a positive M. pneumoniae PCR result in the symptomatic
group.
Variable
Odds Ratio
(95% CI) p-Value
Age ($5 y) 1.56 (0.60–4.02) 0.36
Gender (female) 0.93 (0.46–1.87) 0.84
Season 0.87 (overall)
Spring versus winter 0.80 (0.35–1.81) 0.59
Summer versus winter 0.54 (0.11–2.67) 0.45
Autumn versus winter 0.85 (0.39–2.16) 0.74
Year (2009 versus
2010 and 2011)
5.80 (1.94–17.35) 0.002
Family size ($5 family
members)
1.63 (0.74–3.61) 0.23
Smoking (active or passive) 0.61 (0.30–1.23) 0.17
Presence or history of wheezing 1.96 (0.93–4.13) 0.08
Day-care attendance 0.84 (0.37–1.89) 0.67
Diagnosis (lower RTI) 1.05 (0.46–2.42) 0.91
Hospitalization 1.54 (0.52–4.60) 0.44
The variable ‘‘immunizations’’ was not entered in the regression analysis
because the vast majority of the children were immunized (.95%). Symptoms
and signs were not entered in the regression analysis because these are
represented in the variable ‘‘diagnosis.’’
doi:10.1371/journal.pmed.1001444.t003
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A similar distribution of M. pneumoniae DNA loads was observed
among the asymptomatic and symptomatic children (Figure 3A
and 3B). We did not find a significant correlation between
bacterial load in nasopharyngeal and pharyngeal samples
(Figure 3C). The distribution of bacterial loads was different
among children with a lower RTI and children with an upper RTI
(Figure 3D and 3E). However, both very high and very low
bacterial loads were detected in both subgroups. The study was
not powered to perform a statistical subgroup analysis for this
variable.
To investigate how long M. pneumoniae can persist in the
respiratory tract of children, a longitudinal follow-up study was
performed among children who tested positive for M. pneumoniae by
PCR. In this study, 43 (68%) of the 63 children who were eligible
for inclusion participated in the follow-up study. Of these 43
children, 21 children originated from the asymptomatic group,
and 22 from the symptomatic group. The most common reason
given for declining to participate in the follow-up study was
distance from home to the study site (10/20; 50%). Fifteen of the
21 (71%) asymptomatic children and 19 of the 22 (86%)
symptomatic children in this longitudinal follow-up study tested
negative after 1 mo. Six of the asymptomatic children also tested
positive at 2 mo, and two children also tested positive at 3 mo.
Three of the symptomatic children tested positive at 2 mo, and
none tested positive at 3 mo (Figure 4). To confirm their negative
status, children were tested an additional time after becoming
negative.
We found that the prevalence of a positive ELISA for anti–M.
pneumoniae IgM antibodies was not significantly different in the
asymptomatic group (12.6%, 95% CI 9.4%–15.8%, n=43) and
the symptomatic group (9.2%, 95% CI 6.0%–12.4%, n=26)
(p=0.23). The prevalence of a positive ELISA for anti–M.
pneumoniae IgG antibodies differed significantly (p,0.001) between
the asymptomatic group (25.1%, 95% CI 20.9%–29.3%, n=85)
and the symptomatic group (14.2%, 95% CI 10.4%–18.0%,
n=40). However, when adjusted for age, there was no significant
difference in the prevalence of anti–M. pneumoniae antibodies
between the two groups. The prevalence of a positive ELISA for
anti–M. pneumoniae IgM and IgG was low among children below
the age of 5 y (IgM, 7.3%, 95% CI 3.5%–11.1%; IgG, 8.3%, 95%
CI 4.3%–12.3%) in the asymptomatic group versus in the
symptomatic group (IgM, 6.7%, 95% CI 0.0%–13.4%; IgG,
5.0%, 95% CI 0.0%–5.9%), and much higher among children
above the age of 5 y (IgM, 20.4%, 95% CI 14.1%–26.7%, and
IgG, 50.7%, 95% CI 42.8%–58.5%, in the asymptomatic group;
IgM, 11.9%, 95% CI 7.7%–16.1%, and IgG, 47.6%, 95% CI
Figure 3. M. pneumoniae DNA loads. (A) Pharyngeal bacterial loads (genomic copy number per milliliter on the y-axis) of M. pneumoniae PCR-
positive participants in the asymptomatic group (open squares) and the symptomatic group (filled triangles). (B) Nasopharyngeal bacterial loads
(genomic copy number per milliliter on the y-axis) of M. pneumoniae PCR-positive participants in the asymptomatic group and the symptomatic
group. The bacterial load distribution was compared using the Mann-Whitney U test. (C) Comparison of the bacterial loads in pharyngeal samples and
nasopharyngeal samples for the participants who tested positive for M. pneumoniae in both. Correlation was calculated using the Spearman rank test.
(D and E) Distribution of bacterial loads for upper RTIs (URTI) and lower RTIs (LRTI) in the pharyngeal and nasopharyngeal samples. The line in each
graph represents the median.
doi:10.1371/journal.pmed.1001444.g003
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41.1%–54.1%, in the symptomatic group). The median levels of
IgM and IgG antibodies did not differ significantly between the two
groups (Figures 5A and 5B). The prevalence of a positive ELISA for
anti–M. pneumoniae IgA antibodies was very low in both groups
(2.0%, 95%CI 0.6%–3.4%, versus 0.4%, 95%CI 0.0%–1.1%), and
none of the children below the age of 5 y tested positive for anti–M.
pneumoniae IgA. The serological data did not correspond significantly
with the PCR results (Figure 5C and 5D; Table 4). Interestingly, a
higher percentage of asymptomatic PCR-positive children tested
positive for IgG compared to symptomatic PCR-positive children
(Table 4; 32% versus 15%). However, this difference was not found
to be statistically significant when adjusted for age.
Because an immunoglobulin class switch from IgM to IgG is
generally accepted as evidence of a recent M. pneumoniae infection,
a second serum sample was collected from 233 (72.6%) of the
symptomatic children. From this group, 26 (11.2%) children
developed an immunoglobulin class switch. The agreement
between an immunoglobulin class switch and a positive PCR
result was poor (Kappa= 0.10) (Table 4). Besides age, we did not
find any determinants of an immunoglobulin class switch or a
single positive test for IgM, IgG, or IgA.
Bacterial and viral pathogens do coexist in the respiratory tract, and
co-infection may influence severity of disease. Therefore, we deter-
mined the presence of four other bacterial respiratory pathogens in all
children and the presence of 15 viral respiratory pathogens in a
subsample of the children (n=202). Two or more pathogens were
found in 56% (63/112) of the asymptomatic children and in 55.5%
(50/90) of the symptomatic children. The prevalence of the four
bacterial pathogens is shown in Table 5. As reported previously, the
prevalence of these bacterial species was largely age-dependent [20].
We found a significantly higher prevalence of S. aureus in the
asymptomatic group than in the symptomatic group. However, when
adjusted for age this difference in prevalence was not significant. An
association between the presence of any of these four bacterial species
and M. pneumoniae was not detected. Almost all of the viruses screened
for were detected in both groups (Table 6). We did not perform a
statistical analysis to detect differences in the distribution of cycle
threshold values since our study was not powered for this purpose.
Rhinovirus, bocavirus, and parainfluenzavirus 4 were detected more
frequently in asymptomatic children than in symptomatic children. In
contrast, influenzaviruses A and B, human metapneumovirus, and
respiratory syncytial virus were predominantly detected in symptom-
atic children. The majority of the children (from both groups) tested
positive for more than one pathogen (Figure 6). Group-specific
combinations of pathogens could not be identified. In addition, none of
the viruses were associated with the presence ofM. pneumoniae. Because
of the limited number of M. pneumoniae–positive children without
bacterial and/or viral co-infection, it was not possible to analyze the
influence of bacterial and viral co-infection on disease severity.
Discussion
Statement of Principal Findings
To our knowledge, our study demonstrates for the first time that
M. pneumoniae is carried at high rates in the URT of healthy
children, and that this asymptomatic carriage cannot be differen-
tiated from symptomatic RTI by serology or quantitative PCR. Of
405 healthy children, 21% tested positive for M. pneumoniae in the
URT by PCR. As a result of this high prevalence, the inclusion of
children was terminated at an earlier time point than anticipated
at the start of the study. For now we can conclude that M.
pneumoniae carriage is detectable and its prevalence is higher than
expected, but the actual prevalence of carriage is unreliable.
Prevalence varied between year and season of sampling from 3%
during the spring of 2009 to 58% during the summer of 2010.
These data suggest that carriage follows a cyclic epidemic pattern.
It is tempting to speculate that this fluctuation in prevalence is
related to the known cyclic epidemic pattern of M. pneumoniae
infections that occurs at intervals of 3–7 y, in addition to a
background endemic pattern [4,21]. Longitudinal sampling of M.
pneumoniae–positive asymptomatic children indicated that M.
pneumoniae can be present in the URT without causing disease,
followed by clearance within several weeks.
While previous studies have demonstrated the presence of M.
pneumoniae in seemingly healthy individuals, none of these studies
could draw clear conclusions concerning the actual existence of
carriage of M. pneumoniae [8–15]. Instead, some studies explained
the presence of M. pneumoniae in an asymptomatic individual as a
consequence of a recent infection with this bacterium [14,15].
Other studies were inconclusive because of lack of a specific study
Figure 4. M. pneumoniae DNA loads in the longitudinal study. This figure shows the bacterial DNA loads in the study participants of the
asymptomatic group (A) (open squares) and the symptomatic group (B) (filled triangles) during the follow-up study. Each point represents one visit of
one participant and is connected by a line to the point representing the next visit. On the y-axis the bacterial DNA load (genomic copy number per
milliliter) is shown. On the x-axis the consecutive visits are represented.
doi:10.1371/journal.pmed.1001444.g004
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Figure 5. Anti–M. pneumoniae serum antibody levels. (A and B) Serum IgM (A) and IgG (B) antibody levels (in units/milliliter) are compared
between the asymptomatic group and the symptomatic group (using the Mann-Whitney U test). (C and D) IgM (C) and IgG (D) antibody levels are
plotted against the bacterial DNA load (genomic copy number per milliliter) in all samples. Open squares indicate asymptomatic participants. Filled
triangles indicate symptomatic participants. The horizontal lines in A and B represent the median.
doi:10.1371/journal.pmed.1001444.g005
Table 4. Agreement between PCR and serology.
Test Result Asymptomatic Group Symptomatic Group
PCR Kappa PCR Kappa
Positive Negative Positive Negative
Serology IgM
Positive 11 32 7 13
Negative 55 242 0.06 40 215 0.12
Serology IgA
Positive 4 3 0 1
Negative 62 271 0.08 46 224 20.01
Serology IgG
Positive 16 68 6 25
Negative 50 203 20.01 41 202 0.02
Immunoglobulin class switch
Positive NA NA 7 19
Negative NA NA 31 176 0.10
NA, not applicable.
doi:10.1371/journal.pmed.1001444.t004
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design or because of the use of relatively insensitive diagnostic tools
such as culture [9–12].
Strengths and Weaknesses
Although we have demonstrated the existence of asymptomatic
carriage of M. pneumoniae in children, there are several limitations
to our study. These include the single study site in one city in the
Netherlands, and a limited sample size. Although the sample size
was adequate to address our research questions, it is not large
enough to unravel the dynamics of colonization by M. pneumoniae.
Furthermore, we performed exploratory analyses that show that
M. pneumoniae prevalence is determined by season and year of
sampling, although these analyses did not form part of the original
design of the study. Finally, we have performed a longitudinal
follow-up study that shows the persistence of M. pneumoniae in a
small number of children for up to 4 mo. Although this finding
strongly suggests the existence of carriage, we enrolled only a small
number of children in this part of the study. Future studies are
needed to confirm our results and should aim at finding
determinants of M. pneumoniae carriage. These studies should
preferably have a multicenter design.
Furthermore, we aimed to assess the association between
severity of disease and M. pneumoniae subtype and genomic copy
load. Although we did not find this association in the symptomatic
group, it should be noted that participants positive for M.
pneumoniae subtype 2 were underrepresented overall (as shown in
Table S4). This small number hampered the analysis of this
secondary research question. It might also be argued that these
results are negatively influenced by a general low severity of
disease in our study population and the limited number of
participants with lower RTI (20.9% of all symptomatic children).
Indeed, none of the children in our study were admitted to an
intensive care unit or required respiratory support by mechanical
ventilation. Still, we did find a difference between asymptomatic
and symptomatic children for well-established respiratory patho-
gens such as influenza A and respiratory syncytial virus. We think
that this point underlines the appropriateness of our study
population with regard to severity.
In agreement with other recent studies on M. pneumoniae
infections, a poor correlation was found between data obtained
by PCR and serology [22,23]. Given the excellent performance of
the PCR assay in Quality Control for Molecular Diagnostics
panels, and the validation of the commercial ELISA used, we are
Table 5. Bacterial results in 714 study participants.
Bacterium Asymptomatic Participants (n=393) Symptomatic Participants (n=321) pValue
Str. pneumoniae 109 (27.7) 87 (27.1) 0.92
S. aureus 84 (21.4) 32 (10.0) ,0.001
M. catarrhalis 71 (18.1) 74 (23.1) 0.12
H. influenzae 57 (14.5) 51 (15.9) 0.68
Data are n (percent). The p-values compare the difference in prevalence between the two participant groups indicated by x2 test.
doi:10.1371/journal.pmed.1001444.t005
Table 6. Virology results in 202 study participants.
Virus
Asymptomatic
Participants (n=112)
Symptomatic
Participants (n=90) p-Value
Ct Value, Median (IQR) n (Percent) Ct Value, Median (IQR) n (Percent)
Influenza A virus 20.1 1 (0.9) 23.0 (18.0–33.8) 6 (6.7) 0.03
Influenza B virus Undetectable 0 (0.0) 26.0 1 (1.1) 0.26
Human metapneumovirus 36.7–38.7 2 (1.8) 24.6 (23.0–30.5) 7 (7.8) 0.10
Respiratory syncytial virus A 27.9 1 (0.9) 22.0 (20.0–29.6) 11 (12.2) 0.001
Respiratory syncytial virus B 35.4 1 (0.9) 22.0 (17.3–29.5) 9 (10.0) 0.003
Parainfluenzavirus 1 36.3 (22.0–37.6) 7 (6.3) 25.3 (20.0–26.5) 3 (3.3) 0.34
Parainfluenzavirus 2 35.8 (34.6–35.9) 3 (2.7) 31.1 1 (1.1) 0.43
Parainfluenzavirus 3 20.7. 35.8 2 (1.8) 30.6 (25.1–39.6) 3 (3.3) 0.48
Parainfluenzavirus 4 36.5 (31.9–37.4) 10 (8.9) 38.7 1 (1.1) 0.02
Rhinovirus 26.5 (23.1–31.1) 35 (31.2) 24.7 (22.3–29.4) 17 (18.9) 0.04
Coronavirus 229E Undetectable 0 (0.0) 17.6 1 (1.1) 0.26
Coronavirus OC43 35.6 (28.7–37.3) 5 (4.5) 29.0 (24.1–32.9) 5 (5.6) 0.72
Coronavirus NL63 37.5 (34.8–38.6) 6 (5.4) 27.5 (27.0–38.0) 7 (7.8) 0.49
Bocavirus 30.9 (26.5–34.0) 16 (14.3) 32.0 (28.8–34.0) 3 (3.3) 0.008
Adenovirus 31.9 (27.9–33.8) 17 (15.2) 27.0 (26.2–30.5) 9 (10.0) 0.28
The p-values compare the difference in prevalence between the two participant groups indicated by x2 test.
Ct value, cycle threshold value; IQR, interquartile range.
doi:10.1371/journal.pmed.1001444.t006
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confident that the data obtained by both assays are reliable. It is
possible that the positive serological results simply reflect one or
more previous encounters with M. pneumoniae and are not
necessarily related to a current RTI or carriage of M. pneumoniae
as determined by PCR. However, we did not collect convalescent
serum samples in the asymptomatic group; therefore, we can only
speculate on the prevalence of immunoglobulin class switch or the
levels of convalescent antibodies in this group.
Meaning of the Study
As the pathogenicity of M. pneumoniae was well-documented in
studies with volunteers in the 1950s [24], one can speculate that
asymptomatic carriage of M. pneumoniae may in some cases lead to
symptomatic infection, as is well known to occur for other
pathogens [25]. Obviously, the finding of asymptomatic carriage
of M. pneumoniae has major implications for the interpretation of
the diagnosis of M. pneumoniae infections and for clinical
management, as well as the interpretation of studies of the
etiology of RTD in children. We searched Medline with the terms
‘‘Mycoplasma pneumoniae,’’ ‘‘respiratory tract infection,’’ ‘‘asymp-
tomatic carriage,’’ and ‘‘diagnosis’’ and found that many studies
and some reviews have addressed the performance and clinical
value of different diagnostic methods for M. pneumoniae. It is
striking, however, that these methods are used interchangeably,
and almost every positive result is regarded as indicative of a
symptomatic M. pneumoniae infection. In addition, the occasional
presence of M. pneumoniae in respiratory secretions of healthy
individuals has often been explained either as the first sign of a
developing symptomatic infection or as bacterial persistence
following symptomatic infection [3,11,26–28]. Current guidelines
on community-acquired pneumonia recommend testing for M.
pneumoniae in patients with a high pre-test probability [1,2]. As we
have shown, the available procedures for diagnosis of M.
pneumoniae RTIs in children do not discriminate between carriage
of M. pneumoniae in the respiratory tract and symptomatic M.
pneumoniae infection. Therefore, clinicians may need to readdress
the clinical significance of a positive test result.
Our data indicate that the etiology of RTI in children is
complex. The mere presence of one or more putative pathogens in
the URT does not seem to be the sole determining factor in the
development of a symptomatic RTI. The host immune response,
the timing of colonization, the presence of other pathogens, and
the initial bacterial or viral load may collectively determine
whether carriage proceeds to infection or not. Future studies will
therefore have to focus on how an RTI can be accurately defined
and whether or not it requires treatment.
Conclusion and Future Studies
The results of this study suggest that M. pneumoniae behaves
similarly to many other bacterial species in the respiratory tract.
Future studies at different sites and in different populations are
required to confirm our findings. This finding is important as it
implies that the daily clinical practice of diagnosing M. pneumoniae
RTI is inadequate. Specifically, it does not seem appropriate to use
the detection of M. pneumoniae in the URT by PCR as a method to
diagnose symptomatic RTIs caused by this bacterium. Thus, a
diagnosis of M. pneumoniae–induced RTD cannot be based
exclusively on serology or the detection of M. pneumoniae DNA in
the URT, and caution should be taken in the interpretation of
diagnostic tests for M. pneumoniae. Future studies should address
this diagnostic challenge and aim at finding diagnostic tools that
can differentiate carriage from infection, as well as identifying
factors that may determine progression from asymptomatic
carriage of M. pneumoniae to symptomatic infection.
Supporting Information
Table S1 Comparison between the children for whom consent
was given (enrolled in the study) and the children for whom
consent was not given.
(DOC)
Figure 6. Number of detected viral and bacterial pathogens. The dot plot shows the percentages of participants with 0, 1, 2, 3, or .3 pathogens
present in the URT. On the x-axis the percentages are shown, on the y-axis the number of pathogens is shown. The filled and open triangles show respectively
M. pneumoniae (Mpn) PCR-positive symptomatic children (n=44) andM. pneumoniae PCR-negative symptomatic children (n=46). The filled and open squares
show respectively M. pneumoniae PCR-positive asymptomatic children (n=57) and M. pneumoniae PCR-negative asymptomatic children (n=52).
doi:10.1371/journal.pmed.1001444.g006
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Table S2 Bivariate analysis in the asymptomatic group. This
table shows the prevalence of M. pneumoniae as determined by PCR
for the variables age, gender, immunizations, season of enrollment,
year of enrollment, family size, smoking, presence or history of
wheezing, day-care attendance, RTI prior to enrollment, and RTI
in the month after enrollment.
(DOC)
Table S3 Bivariate analysis in the symptomatic group. This
table shows the prevalence of M. pneumoniae as determined by
PCR for the variables age, gender, immunizations, season of
enrollment, year of enrollment, family size, smoking, presence or
history of wheezing, day-care attendance, symptoms present at
the time of enrollment, diagnosis (presence of a lower RTI), and
hospitalization.
(DOC)
Table S4 The distribution of the different M. pneumoniae
genotypes (i.e., subtype 1 and 2) in the asymptomatic and
symptomatic groups.
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Text S1 Study protocol.
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Editors’ Summary
Background. Pneumonia (a form of acute respiratory infec-
tion) is the single largest cause of death in children worldwide,
killing an estimated 1.2 million children aged five and under
every year, particularly in South Asia and sub-Saharan Africa. In
these settings, bacterial infections with Streptococcus pneumo-
niae andHaemophilus influenzae are themost common causes of
bacterial pneumonia. However, in high-income settings, bacterial
infection with Mycoplasma pneumoniae is a major cause of
upper and lower respiratory tract infections in children: over one-
third of childhood cases of community-acquired pneumonia that
require admission to a hospital are caused by M. pneumoniae.
Currently, diagnosis of M. pneumoniae infections relies on the
detection of antibodies against M. pneumoniae in the blood or
detection of bacterial DNA in samples from the upper respiratory
tract through polymerase chain reaction (PCR) tests.
Why Was This Study Done? Other bacteria, such as
Streptococcus pneumoniae, are commonly present in children
without causing infection, a situation known as asymptom-
atic carriage. However, to date, it is unknown whether M.
pneumoniae is also commonly carried in the upper respira-
tory tract of children without causing symptoms or leading
to infection. The possibility of asymptomatic carriage of M.
pneumoniae could have major implications for the interpre-
tation of the results of diagnostic tests and also for clinical
management. So in this study conducted in The Netherlands,
the researchers investigated whether asymptomatic carriage
of M. pneumoniae exists and also whether symptomatic
infection could be differentiated from asymptomatic carriage
by current diagnostic methods.
What Did the Researchers Do and Find? Between 2008
and 2011, the researchers recruited children aged between
three months and 16 years attending a hospital in Rotterdam
for an elective surgical procedure (asymptomatic group) or
admitted with a respiratory tract infection (symptomatic
group). All children had blood tests and respiratory samples
(nasopharyngeal swab) taken on admission and were tested
for other pathogens. The researchers invited children who
tested positive forM. pneumoniae by PCR to attend for further
follow-up and tested them monthly for the presence of M.
pneumoniae DNA in the upper respiratory tract until the test
was negative on two occasions. Using these methods, the
researchers recruited 726 children over the study period—405
in the asymptomatic group and 321 in the symptomatic
group. The researchers found that the prevalence of M.
pneumoniae did not differ between the asymptomatic group
and the symptomatic group, with prevalences of 21.2% and
16.2%, respectively (the prevalence ofM. pneumoniae also did
not differ significantly between those with lower versus upper
respiratory infection). There were also no differences in
prevalence in the asymptomatic and symptomatic groups
when diagnosed using blood tests. The researchers found a
high rate of multiple, coexisting bacterial and viral pathogens
in both asymptomatic and symptomatic children: two or more
pathogens were found in 56% (63/112) of the asymptomatic
children and in 55.5% (50/90) of the symptomatic children.
Furthermore, season and the year of enrollment affected the
prevalence of M. pneumoniae in the asymptomatic group,
ranging from 3% during the spring of 2009 to 58% during the
summer of 2010. Finally, of the 21 children from the
asymptomatic group who participated in the follow-up study,
15 (71%) tested negative within one month, and in the
symptomatic group, 19 of 22 children (86%) tested negative
after the first visit.
What Do These Findings Mean? These findings show
that M. pneumoniae is carried at high rates in the upper
respiratory tracts of healthy children, and that this asymp-
tomatic carriage cannot be differentiated from symptomatic
respiratory tract infection by diagnostic tests (serology or
PCR). As the prevalence of M. pneumoniae varied between
year and season, carriage of M. pneumoniae may follow a
cyclic epidemic pattern. This study is from a single study site
in one city in The Netherlands, with a relatively small number
of children, and so these findings may not be generalizable
to other populations. However, as this study suggests that
current diagnostic tests do not discriminate between
carriage and infection, clinicians may need to reconsider
the clinical significance of a positive test result. Future
studies are needed to address this diagnostic challenge and
also to investigate possible factors that may affect the
progression of asymptomatic carriage of M. pneumoniae to
symptomatic infection.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001444.
N MicrobeWiki has more information on M. pneumoniae
N Lab Tests Online explains current tests for M. pneumoniae
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